Op0023 a Randomized, Double-blind Trial Comparing Secukinumab 300 Mg and 150 Mg at Week 52 in Patients With Ankylosing Spondylitis Who Did Not Achieve Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 Mg
Year: 2022
Type: conference-abstract
Source: Annals of the Rheumatic Diseases
Institutions: Oregon Health & Science University, Altoona Center for Clinical Research, Altoona Arthritis and Osteoporosis Center, University Hospitals Cleveland Medical Center, Case Western Reserve University, University of Utah, Lake City VA Medical Center, University of Washington, Swedish Medical Center, Novartis (United States), Novartis (India), University of California, San Francisco
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Oak Foundation, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, GlaxoSmithKline, Sanofi, Gilead Sciences, Celgene, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Parker Institute for Cancer Immunotherapy, Novo Nordisk Fonden, Galderma, Swedish Orphan Biovitrum, Sun Pharma
Awards: G1331633265, G4112386259
OpenAlex ID: W4283575436